Neuphoria Therapeutics (NEUP) FCF Margin (2024 - 2025)
Neuphoria Therapeutics (NEUP) reported FCF Margin of 26850.85% for Q2 2025, up 35065.18% on a QoQ basis from 76.36% in Q1 2025.
Neuphoria Therapeutics (NEUP) has 2 years of FCF Margin data on file, last reported at 26850.85% in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 27,022.48% |
| Mar 31, 2025 | 76.36% |
| Dec 31, 2024 | -506.72% |